Inmune Bio, Inc. current report, 29 September 2020

Business Context and Reporting Period

Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2020
Reporting Period: Single event date (September 29, 2020)
Business Context: The filing discloses the presentation of a Key Opinion Leader (KOL) webinar focused on treatment-resistant depression (TRD).

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is an event disclosure and does not contain financial statements or performance metrics.

Material Changes

No material financial changes versus a prior comparable period are reported in this document. The filing solely addresses the scheduling and content of a specific corporate event (the KOL webinar).

Guidance, Outlook, and Risks

Management Commentary: The Company is hosting a webinar on September 29, 2020, regarding treatment-resistant depression. The presentation is filed as Exhibit 99.1.
Outlook/Guidance: The filing text does not provide a clear value for future financial guidance or operational outlook.
Risks/Contingencies: No specific risks or contingencies are detailed in the body of this report.

Investor Verification Checklist

  • Verify the content of the KOL webinar presentation filed as Exhibit 99.1.
  • Confirm the date and time of the webinar event (Tuesday, September 29, 2020).
  • Review the Company's latest 10-Q or 10-K for actual financial performance data, as this 8-K contains none.